Obesity is a complex, chronic disease. It involves many factors—environmental, genetic, and behavioral. For too long, many people thought it was just about overeating and laziness. This belief creates stigma, making those affected feel like failures. Dr. Danny Issa from UCLA explains, “Patients often see obesity as a personal failure rather than a medical issue, leading to disappointment with themselves and frustration with the healthcare system.”
Metabolism varies significantly from person to person. It’s not just diet or exercise at play. Stress, lack of sleep, and emotional factors often get overlooked. Understanding the full picture is essential for effective treatment.
In recent years, treatments like glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have changed how we approach obesity. In June 2021, semaglutide was approved by the FDA for weight management, and tirzepatide followed suit in November 2023. These treatments are making it easier for patients to seek help, but they aren’t perfect solutions. Dr. Issa notes that while more people are exploring medical therapies, many don’t respond well to them, and side effects can lead to discontinuation.
For those not seeing results from medication, endoscopic bariatric treatments can be an option. Dr. Jennifer Kolb, also at UCLA, says these methods work well for patients who haven’t had success with diet or who avoid surgery. Endoscopic sleeve gastroplasty (ESG) is a promising procedure. It modifies the stomach to reduce food intake and has shown significant weight loss in clinical studies with low complication risk.
Candidates for ESG typically have a BMI between 30 and 50, and a healthy stomach is crucial. This method could be especially beneficial for those needing to lose weight before qualifying for other procedures, like knee surgeries.
Interestingly, ESG may pose less risk for developing gastroesophageal reflux disease (GERD), a common issue after other surgeries. Studies show that only about 1% of ESG patients develop GERD, compared to 20% of those who have had laparoscopic sleeve gastrectomy.
Weight regain is common after weight-loss surgeries. Research shows 20% to 50% of patients may regain weight within five to seven years. Dr. Alireza Sedarat mentions transoral outlet reduction (TORe) as a safe solution for patients who have gained weight after Roux-en-Y bypass. This method slows stomach emptying, helping patients feel full longer and manage their weight.
Obesity often overlaps with other health issues, such as diabetes. Dr. Adarsh M. Thaker emphasizes the need to consider these related conditions in treatment plans. The CDC reports that U.S. healthcare spends a startling $1 out of every $4 on diabetes care, highlighting its urgency.
Exciting research is underway at UCLA on duodenal mucosal resurfacing (DMR), a procedure that aims to reset metabolism by replacing diseased duodenal tissue. Initial studies show promise in preventing weight regain after GLP-1 RA treatment ends, marking a potential game-changer in obesity management.
A collaborative approach at UCLA combines expertise from various specialties, ensuring a well-rounded treatment for each patient. Programs like PRO (Program for Reducing Obesity) and COMET (Center for Obesity and METabolic Health) gather a multidisciplinary team, offering tailored care. As we look ahead, endoscopic methods are gaining traction, especially with new coding for procedures like ESG expected to improve insurance coverage.
In summary, tackling obesity requires understanding its complexities, addressing stigma, and combining various treatment methods. With continued research and collaboration, there’s hope for more effective strategies to combat this prevalent health issue.
